The molecular classification ushers in a new era for the treatment of advanced and recurrent endometrial cancer
Authors:
Open Access
- 12 January 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1761159
Abstract
Endometrial cancer is among the most common malignant tumors of the female reproductive system, with an increasing incidence globally over the past decade and ranking first among gynecological malignancies in developed countries. Although early-stage prognosis is favorable, the mortality rate of advanced and recurrent endometrial cancer remains high, posing a significant clinical challenge. Molecular classification systems, such as TCGA and ProMisE, have identified four distinct molecular subtypes: POLE-mutant (POLEmut), mismatch repair-deficient (MMRd), no specific molecular profile (NSMP), and p53-abnormal (p53abn), each exhibiting significantly different biological behaviors, recurrence patterns, and treatment responses. “Chemotherapy-free” strategies show potential for specific subtypes and offer new avenues for reducing toxicity. Faced with challenges, such as tumor heterogeneity and drug resistance mechanisms, future research should focus on optimizing standardized molecular classification protocols, exploring novel combination therapies, and integrating real-world evidence. A personalized treatment system centered on molecular classification that considers the quality of life and treatment accessibility is crucial for precision medicine in advanced and recurrent endometrial cancer.Keywords
This publication has 72 references indexed in Scilit:
- SEOM-GEICO clinical guidelines on endometrial cancer (2025)Clinical and Translational Oncology, 2025
- Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative treatmentsDiscover Oncology, 2025
- Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitorsInternational Journal of Clinical Oncology, 2025
- Immunotherapy for endometrial cancerInternational Journal of Clinical Oncology, 2024
- Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in EuropeArchives of Gynecology and Obstetrics, 2024
- Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial CancerCurrent Treatment Options in Oncology, 2022
- Clinical Profile and Survival Outcome of Endometrial Cancer with p53 MutationIndian Journal of Surgical Oncology, 2022
- Cancer of the corpus uteri: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- Postoperative chemotherapy as adjuvant treatment for endometrioid adenocarcinoma: early stage vs late stageCancer Chemotherapy and Pharmacology, 2019
- Clinical Behavior and Treatment of Endometrial Cancer2016